A Complete Response Letter is an official communication issued by the FDA to a drug or biologic sponsor indicating that a regulatory application — such as a BLA (Biologics License Application) or NDA (New Drug Application) — cannot be approved in its current form. A CRL outlines the deficiencies that must be addressed before approval can be granted, which may relate to CMC data, clinical data, manufacturing inspections, or labeling requirements.
